Israel Business Today - Teva drug approval.(Teva Pharmaceutical Industries)
Teva Pharmaceutical Industries (NASDAQ-TEVIY) of Jerusalem announced that the U.S. Food and Drug Administration approved Teva’s sixth drug application in 1995. The application permits Teva to manufacture and market Nortriptyline Hydrochloride capsules. Nortriptyline is a generic equivalent of Sandoz’ antidepressant product, Pamelor. Teva reported that several generic equivalents of Nortriptyline already are available.
Related Results
Trust, E-innovation and Leadership in ChangeForeign Banks in United States Since World War II: A Useful FringeBuilding Your Brand With Brand Line ExtensionsThe Impact of the Structure of Debt on Target GainsProject Management Standard Program
Teva reported that previous …
Read the rest of this article with a Free Trial at HighBeam Research.
